Parse Biosciences and Graph Therapeutics announced a strategic partnership to build a large, functional immune perturbation atlas profiling hundreds of millions of human cells. Graph will run patient‑derived, lab‑in‑the‑loop perturbation assays while Parse’s GigLab/Evercode platform will generate massively scaled single‑cell whole‑transcriptome datasets. Gregory Vladimer, PhD, of Graph framed the effort as closing the gap between AI predictions and clinical reality. The atlas aims to accelerate AI‑first target selection for autoimmune and immune‑mediated diseases and reduce late‑stage translational risk by systematically mapping cellular responses across contexts.